Search
News
Emese Zsiros, MD, PhD, to Lead Gynecologic Oncology Program at Roswell Park
News
Landmark Study Led by Roswell Park Expert Shows Survival Benefit of Immunotherapy in Resistant Ovarian Cancer
News
Roswell Park Study: Chronic Opioid Use Reduced by Limiting Prescribed Opioids After Surgery
… use,” appears today in JAMA Oncology . It was led by Emese Zsiros, MD, PhD , the Shashi Lele, MD, Endowed Chair and … (from 6.1% pre-protocol to 2.7% post-protocol). Dr. Zsiros and her team relied on New York State’s rigorous … when post-surgical pain would no longer be an issue. Dr. Zsiros notes that data from the Centers for Disease Control …
News
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer
News
Roswell Park Team Assesses Addition of Complement Inhibitor Drug to Immunotherapy for Ovarian Cancer
… it has been evaluated for the treatment of cancer. Emese Zsiros, MD, PhD, FACOG , serves as principal investigator for … Research Project Grant (R01) awarded to Drs. Zsiros and Segal. “The tumor microenvironment of ovarian … cancer strongly suppresses the immune system,” says Dr. Zsiros, who is Chair of the Department of Gynecologic …
News
Roswell Park Researchers Uncover Clues to Immunotherapy Response in Patients with Recurrent Ovarian Cancer
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Clinical Trial
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients with Platinum-Resistant Ovarian Cancer
… in Patients with Platinum-Resistant Ovarian Cancer I Zsiros, Emese This phase 1 study evaluates the safety, …
Clinical Trial
NRG-GY032: A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
News